Kurma Partners Employee Directory
Venture Capital and Private Equity PrincipalsÎle-de-france, France11-50 Employees
Kurma Partners is a European venture capital group focused on healthcare, headquartered in Paris, France. It operates two dedicated franchises, Kurma Biofund for therapeutics (currently KBIII) and Kurma Diagnostics for diagnostics and digital health (Kurma Dx2). The firm has approximately €470 million under management and a team of 11–50 employees. It engages in healthcare venture investments across the sector, with involvement in companies such as Raidium (seed round co-led with Newfund in 2024), Nuclidium (Series B led by Kurma Growth Opportunities Fund in 2025), Alveus Therapeutics (Series A in 2026), SciRhom (Series A in 2024), and Shorla Pharma (Series B in 2023). The firm has also pursued corporate collaborations, including a 2023 partnership with Samsung Biologics to support its portfolio companies.